Exploring Heart Failure Drugs

Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American College of Cardiology’s Annual Scientific Session (ACC.26) that took place in March in New Orleans, Louisiana.

Anumana is an AI-driven health technology company committed to transforming cardiovascular care. Co-founded by nference and Mayo Clinic, Anumana is developing software-as-a-medical-device (SaMD) solutions that apply multimodal AI to support early detection, clinical decision-making, and intraoperative guidance across the continuum of care.

May 1, 2026 — On May 14, Cleerly and interventional cardiologist Neerav Sheth, MD, will present a free webinar on "Plaque-Informed Ischemia: A New

May 12, 2026 — Johnson & Johnson has launched its Shockwave C2 Aero Coronary IVL catheter designed for improved deliverability, enhanced lesion crossing and new repositioning capabilities for treating calcified coronary artery disease (CAD).1,2,3 The next-generation coronary IVL catheter leverages Shockwave IVL’s unique mechanism of action and the safety and effectiveness profile of its legacy catheters, expanding the company’s market-leading IVL portfolio.

May 10, 2026 — Results from the first randomized trial evaluating microRNA inhibition in heart failure were presented today in Barcelona at Heart Failure 2026,1 the annual congress of the Heart Failure Association of the European Society of Cardiology.

May 7, 2026 — AccurKardia, a provider of ECG-based diagnostics technology, recently announced that AK+ Guard has been selected as winner of the “Best New ECG Technology Solution” award in the 10th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes innovative companies, technologies and products in the global digital health and medical technology market.

May 1, 2026 — Echo IQ  recently announced it has deployed its AI-based decision support software for the assessment of severe aortic stenosis, EchoSolv AS, with the Mount Sinai Health System in New York.

May 7, 2026 — Bayer has announced positive topline results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital that evaluated the investigational PET/CT radiotracer I 124 evuzamitide.1,5 The study met the primary endpoints of sensitivity (the ability of a test to identify individuals who have the condition) and specificity (the ability of a test to identify individuals who do not have the condition) for the diagnosis of cardiac amyloidosis based on visual scan interpretation.1 Bayer plans

May 1, 2026 — Retia Medical recently announced the first public presentation of results from its non-invasive cardiac output algorithm, which estimates cardiac output using signals from sensors already placed on patients as standard of care: a pulse oximeter and a non-invasive blood pressure cuff. No additional hardware is required.

May 6, 2026  — Image Analysis Group (IAG), a global imaging CRO headquartered in London, U.K., and HeartcoR Solutions, LLC, announced a strategic partnership to deliver fully integrated cardiac safety monitoring and imaging services to pharmaceutical and biotechnology sponsors worldwide.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now